New hope for rare muscle disease: experimental drug enters human trials
NCT ID NCT06131983
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 31 times
Summary
This study tests an experimental drug called ARO-DUX4 in 60 adults and teens with facioscapulohumeral muscular dystrophy type 1 (FSHD1), a genetic condition that causes muscle weakness. The main goal is to check the drug's safety and how it moves through the body. Participants receive either the drug or a placebo, and some may continue treatment in a later study.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FACIO-SCAPULO-HUMERAL DYSTROPHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
WITHDRAWNBangkok, 10700, Thailand
-
Research Site 1
RECRUITINGBirtinya, Queensland, 4575, Australia
-
Research Site 1
RECRUITINGMontreal, Quebec, H3A2B4, Canada
-
Research Site 1
RECRUITINGUlm, 89081, Germany
-
Research Site 1
RECRUITINGMilan, 20162, Italy
-
Research Site 1
RECRUITINGLeiden, 2333, Netherlands
-
Research Site 1
RECRUITINGAuckland, 1010, New Zealand
-
Research Site 1
RECRUITINGValencia, 46026, Spain
-
Research Site 2
RECRUITINGLiverpool, New South Wales, 2170, Australia
-
Research Site 2
NOT_YET_RECRUITINGCalgary, Alberta, T2N4Z6, Canada
-
Research Site 2
RECRUITINGMünchen, 80336, Germany
-
Research Site 2
RECRUITINGRoma, 00168, Italy
-
Research Site 2
RECRUITINGMadrid, 28034, Spain
-
Research Site 3
RECRUITINGAuchenflower, Queensland, 4066, Australia
-
Research Site 3
RECRUITINGEdmonton, Alberta, T6G2G4, Canada
-
Research Site 3
RECRUITINGBarcelona, 08035, Spain
-
Research Site 4
RECRUITINGMelbourne, Victoria, 3004, Australia
Conditions
Explore the condition pages connected to this study.